Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 1
2017 2
2018 1
2019 1
2020 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.
Leserer S, Graf T, Franke M, Bogdanov R, Arrieta-Bolaños E, Buttkereit U, Leimkühler N, Fleischhauer K, Reinhardt HC, Beelen DW, Turki AT. Leserer S, et al. Among authors: buttkereit u. Front Immunol. 2023 Mar 20;14:1082727. doi: 10.3389/fimmu.2023.1082727. eCollection 2023. Front Immunol. 2023. PMID: 37020562 Free PMC article.
Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Kordelas L, Schwich E, Lindemann M, Heinemann FM, Buttkereit U, Horn PA, Beelen DW, Rebmann V. Kordelas L, et al. Among authors: buttkereit u. Front Immunol. 2020 Jan 10;10:3027. doi: 10.3389/fimmu.2019.03027. eCollection 2019. Front Immunol. 2020. PMID: 31998310 Free PMC article.
Clinical Utility of Quantitative PCR for Chimerism and Engraftment Monitoring after Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Ahci M, Stempelmann K, Buttkereit U, Crivello P, Trilling M, Heinold A, Steckel NK, Koldehoff M, Horn PA, Beelen DW, Fleischhauer K. Ahci M, et al. Among authors: buttkereit u. Biol Blood Marrow Transplant. 2017 Oct;23(10):1658-1668. doi: 10.1016/j.bbmt.2017.05.031. Epub 2017 Jun 8. Biol Blood Marrow Transplant. 2017. PMID: 28603070 Free article.
Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S. Nowrousian MR, et al. Among authors: buttkereit u. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14. doi: 10.1158/1078-0432.CCR-05-0486. Clin Cancer Res. 2005. PMID: 16361557
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
Schütt P, Buttkereit U, Brandhorst D, Lindemann M, Schmiedl S, Grosse-Wilde H, Seeber S, Nowrousian MR, Opalka B, Moritz T. Schütt P, et al. Among authors: buttkereit u. Cancer Immunol Immunother. 2005 May;54(5):506-12. doi: 10.1007/s00262-004-0633-6. Epub 2004 Nov 20. Cancer Immunol Immunother. 2005. PMID: 15750834 Free PMC article.
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR. Schütt P, et al. Among authors: buttkereit u. Ann Hematol. 2005 Sep;84(9):594-600. doi: 10.1007/s00277-005-1007-7. Epub 2005 Mar 3. Ann Hematol. 2005. PMID: 15744524 Clinical Trial.